The U.S. FDA has approved SPRAVATO® (esketamine) as the first monotherapy for adults suffering from treatment-resistant depression. This decision follows the Priority Review based on significant data demonstrating that SPRAVATO® achieved its primary endpoint at four weeks, showing a rapid and superior improvement in depressive symptoms.
Vero’s thoughts on the news:
This FDA approval of SPRAVATO® as a monotherapy for treatment-resistant depression is a notable advancement in the field of mental health. The rapid efficacy of SPRAVATO® can potentially offer hope to those who have not responded to conventional treatments. From a tech perspective, the integration of this new treatment method might influence the development of mental health apps, perhaps leading to innovations that incorporate digital monitoring and support tools to complement the pharmacological treatment. The approval highlights the importance of continuous R&D and presents an opportunity for tech solutions to play a supportive role in patient care.
Source: SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression – PR Newswire
Hash: a93d4e208c02a8407ec28aafc2c17bb856af89ddfb2ffde211e8e6381f8a9525
